id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-344560-662pfa61	Yamamoto, Norio	Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro	2020-04-08		.txt	text/plain	1419	96	71	After the outbreak of severe acute respiratory syndrome (SARS) in 2003, screening of approved drugs identified at least two human immunodeficiency virus type-1 (HIV-1) protease inhibitors, lopinavir and nelfinavir, as compounds that inhibited SARS-CoV replication in vitro 3, 4 . Among these inhibitors tested, the high concentrations of drugs were required to inhibit SARS-CoV-2 replication in amprenavir (EC 50 = 31.32 µM, CC 50 > 81 µM, SI > 2.59), darunavir (EC 50 = 46.41 µM, CC 50 > 81 µM, SI > 1.75), and indinavir (EC 50 = 59.14 µM CC 50 > 81 µM, SI > 1.37) (Fig. 1g , h, i, j). Lopinavir, which has been clinically tested in patients with SARS and COVID-19, blocked SARS-CoV-2 replication at a low concentration range and its SI was relatively high among nine inhibitors (EC 50 = 5.73 µM, CC 50 = 74.44 µM, SI = 12.99) (Fig. 1b, j) . These results suggest that nelfinavir, lopinavir, and tipranavir can achieve EC 50 of each drug in human and are effective in the treatment of COVID-19 patients.	./cache/cord-344560-662pfa61.txt	./txt/cord-344560-662pfa61.txt